Needle in a Haystack Antibody Unlocking A Fundamental Pathway in Disease Biology: Bhaskar Srivastava

If you're in biotech, immunology, or drug development - this is the episode you’ve been waiting for.We’re joined by Dr. Bhaskar Srivastava, Chief Medical Officer at Triveni Bio, whose career has spanned over 10 years across J&J, Nimbus, and now Triveni Bio, one of the most ambitious autoimmune biotech startups on the scene.In this episode, Bhaskar dives deep into:· How Triveni is building a first-in-class pipeline targeting the kallikrein system - a bold bet to treat severe skin and inflammatory conditions by tackling novel biology.· What it means to be a founder’s CMO, and how great science needs the right development strategy to make a difference.· Candid stories from his past roles at Nimbus (which sold its TYK2 program to Takeda for $4B) and Janssen, where he helped guide first-in-class therapies from Phase 1 to pivotal trials.· Why bispecifics may be risky but worth it, and how Triveni is using novel biologics to crack tough diseases like atopic dermatitis.· Advice for executives: how to balance ambition and discipline, when to say no, and why choosing the right team members matters as much as the science.🎙 Bhaskar doesn’t just talk science - he connects molecular biology to patient need, clinical strategy, and company vision with clarity and purpose.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentBhaskar Srivastava CMO at Triveni BioLinkedIn: https://www.linkedin.com/in/bhaskar-srivastava-355a9ab1/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings15:44 Success & Growth in Biotech28:43 Investing in Biotech34:23 The Future of Dermatology & Triveni Bio#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.